Preview

Современная ревматология

Расширенный поиск

Перспективы применения целекоксиба у пациентов с анкилозирующим спондилитом: влияние на замедление прогрессирования заболевания

https://doi.org/10.14412/1996-7012-2012-752

Полный текст:

Аннотация

Анкилозирующий спондилит (АС) — одно из основных воспалительных заболеваний, при котором поражаются позвоночник и суставы. Основой лечения АС остаются нестероидные противовоспалительные препараты (НПВП), которые не только уменьшают болевые ощущения и ригидность, но и замедляют рентгенологическое прогрессирование заболевания. Одним из эффективных и безопасных НПВП, перспективных для лечения АС, является целекоксиб.

Литература

1. <div><p>Khan M.A. Update on spondyloarthropathies. Ann Int Med 2002; 136: 896—907.</p><p>Gran J.T., Husby G., Hordvik M. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann Rheum Dis 1985; 44: 359-67.</p><p>Kaipiainen-Seppanen O., Aho K., Heliovaara M. Incidence and prevalence of ankylosing spondylitis in Finland. J Rheum 1997; 24: 496-9.</p><p>Van der Linden S.M., Valkenburg H.A., de Jongh B.M. et al. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthr Rheum 1984; 27: 241-9.</p><p>Trontzas P., Andrianakos A., Miyakis S. et al. Seronegative pondyloarthropathies in Greece: a population-based study of prevalence, clinical pattern, and management. The ESORDIG study. Clin Rheum 2005; 24: 583-9.</p><p>Насонов Е.Л. Нестероидные противовоспалительные препараты при ревматических заболевания: стандарты лечения. РМЖ 2001; 7—9: 265—70.</p><p>Zochling J., van der Heijde D., Burgos-Vargas R. et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442-52.</p><p>Braun J., Davis J., Dougados M. et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 316-20.</p><p>Gossec L., van der Heijde D., Melian A. et al. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 2005; 64: 1563-7.</p><p>Dougados M., Behier J., Jolchine I. et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthr Rheum 2001; 44: 180-5.</p><p>Barkhuizen A., Steinfeld S., Robbins J. et al. Celecoxib is efficacious in treating the signs and symptoms of ankylosing spondylitis. Ann Rheum Dis 2005; 64(Suppl. 3): 338.</p><p>Wanders A., Heijde D., Landewe R. et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthr Rheum 2005; 52: 1756-65.</p><p>Boersma J.W. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. Scand J Rheum 1976; 5: 60-4.</p><p>Zhang X., Schwarz E.M., Young D.A. et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002; 109: 1405-15.</p><p>Siegle I., Klein T., Backman J.T. et al. Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthr Rheum 1998; 41: 122-9.</p><p>Ijiri K., Matsunaga S., Fukuda T. et al. Indomethacin inhibition of ossification induced by direct current stimulation. J Orthop Res 1995; 13: 123-31.</p><p>Neal B., Rodgers A., Dunn L. et al. Nonsteroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty. Cochrane Database Syst Rev 2000; 3: CD001160.</p><p>Sieper J., Klopsch T., Richter M. et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis 2008; 67: 323-9.</p><p>Hajjal H.E.L., Marcelis A., Devogelaer J.-P. et al. Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. J Rheum 2003; 30: 2444-51.</p><p>Mastberger S.C., Lafeber F.P., Bijlsma J.W. Selective COX-2 inhibition prevents proin-flammatory cytocin-inducedcartilage damage. Rheumatology 2002; 41: 801-8.</p><p>Hall F.C., Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology 2005; 44: 1473-82.</p><p>Peters M.J., van der Horst-Bruinsma I.E., Dijkmans B.A. et al. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Sem Arthr Rheum 2004; 34: 585-92.</p><p>Silverstein F., Faich G., Goldstein J. et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55.</p><p>Singh G., Fort J.G., Goldstein J.L. et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006; 119: 255-66.</p><p>Arber N., Eagle C., Spicak J. et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355: 885-95.</p><p>Bertagnolli M.M., Eagle C.J., Zauber A.G. et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 873-84.</p><p>Trelle S., Reichenbach S., Wandel S. et al. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis. BMJ 2011; 11(342): 7086.</p><p>Lanas A., Garcia-Rodriguez L.A., Arroyo M.T. et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55(12): 1731-8.</p><p>Fries J.F., Murtagh K.N., Bennett M. et al. The rise and decline of nonsteroidal antiinflammatory drugassociated gastropathy in rheumatoid arthritis. Arthr Rheum 2004; 50: 2433-40.</p><p>Singh G., Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective—1997. Arthritis, rheumatism, and aging medical information system. J Rheum 1998; 51(Suppl.): 8-16.</p><p>Solomon D.H. Selective cyclooxygenase 2 inhibitors and cardiovascular events. Arthr Rheum 2005; 52: 1968-78.</p><p>Bensen W., Zhao S., Burke T. et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheum 2000; 27: 1876-83.</p><p>Goldstein J., Silverstein F., Agrawal N. et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1681-90.</p><p>Singh G., Triadafilopoulos G., Agrawal N. et al. Safety without borders: upper and lower gastrointestinal safety of celecoxib in a pooled analysis of 52 prospective, randomised, doubleblinded, parallelgroup clinical trials [abstract]. Arthr Rheum 2010; 62(Suppl. 10): 2205.</p><p>Chan F.K., Lanas A., Scheiman J. et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376(9736): 173-9.</p><p>Каратеев А.Е. Целекоксиб, эторикоксиб, мелоксикам и нимесулид: сравнение достоинств и недостатков. Совр. ревматол. 2011; 2: 9-20.</p></div><br />


Для цитирования:


Корсакова Ю.Л. Перспективы применения целекоксиба у пациентов с анкилозирующим спондилитом: влияние на замедление прогрессирования заболевания. Современная ревматология. 2012;6(3):74-77. https://doi.org/10.14412/1996-7012-2012-752

For citation:


Korsakova Yu.L. Prospects for the use of celecoxib in patients with ankylosing spondylitis: impact on retarding disease progression. Modern Rheumatology Journal. 2012;6(3):74-77. (In Russ.) https://doi.org/10.14412/1996-7012-2012-752

Просмотров: 575


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)